🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease

Recruitingn/aAges 18 Years - anyAllElazıg Fethi Sekin Sehir Hastanesi
NCT07480720 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years Diagnosis of Graves' disease (for the patient group) No known thyroid disease in healthy control participants Availability of optical coherence tomography (OCT) measurements and laboratory data Time interval between OCT examination and blood sampling ≤ 10 days Exclusion Criteria: * Presence of glaucoma, optic neuropathy, or retinal vascular diseases Macular diseases, uveitis, or severe refractive error (high myopia \>6 diopters) Diabetic retinopathy History of previous intraocular surgery History of active infection, malignancy, or systemic inflammatory disease Poor-quality OCT measurements (segmentation errors or low signal strength)
💊

What it tests

  • Not listed
📍

Where

1 site
Fethi Sekin City Hospital
Elâzığ, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy